SuppreMol, which is led by CEO Dr Peter Buckel, has also been awarded research funding of €1.6m by the German Federal Ministry of Education and Research (BMBF).
SuppreMol GmbH, a Martinsried/Munich Germany-based biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, closed a €15.5m Series C financing round.
The round was led by MIG AG and BioMedPartners AG, with participation from existing investors Santo Holding GmbH, KfW Mittelstandsbank, Bayern Kapital and Max-Planck-Gesellschaft and new investor FCP Biotech Holding GmbH.
SuppreMol intends to use the proceeds for the GMP production and further clinical studies of its lead candidate, SM101, a recombinant human soluble Fc gamma receptor IIb for the treatment of:
– Primary Immune Thrombocytopenia (ITP), a serious bleeding condition characterized by deficient blood clotting due to auto-antibodies destroying the body’s platelets, and
– Systemic Lupus Erythematosus (SLE), a chronic inflammatory autoimmune disease of unknown etiology affecting multiple organs, which can lead to organ failure.
The company plans to initiate a Phase IIa study in SLE mid next year.
In addition, the funds will be used for the preclinical development of an anti-FcgRIIb monoclonal antibody, which, due to the different properties of this molecule compared to SM101, may have beneficial therapeutic potential in certain autoimmune diseases.